natgillin/translations-raw huggingface dataset:
The Commission does consider that all possibilities to reinforce the fight against the smuggling of migrants and against trafficking of human beings should be explored.
Komisija sicer meni, da je treba preučiti vse možnosti za okrepitev zatiranja tihotapljenja migrantov in trgovine z ljudmi.
The Commission does however accept the remaining technical changes within 3(h) in principle, whilst using language developed in part through Council work.
Komisija načeloma sprejema ostale tehnične spremembe v 3(h), z uporabo jezika, deloma razvitega med delom Sveta.
The Commission does in principle see benefits in establishing standards for the treatment of WEEE, and is currently supporting a project developing such standards to be used on a voluntary basis.
Komisija načeloma vidi koristi v uveljavitvi standardov za obdelavo OEEO in trenutno podpira projekt za razvoj prostovoljne uporabe takšnih standardov.
The Commission does not accept amendment 12 modifying Article 22 of Directive 2001/18/EC on free circulation, because the proposal will allow Member States to restrict exclusively the cultivation of GMOs on their territory and not the trade or import of GM or conventional seeds, food and feed.
Komisija ne sprejema spremembe 12, ki spreminja člen 22 Direktive 2001/18/ES o prostem pretoku, ker bo predlog državam članicam omogočal, da omejijo izključno gojenje GSO na svojem ozemlju, ne pa trgovine ali uvoza gensko spremenjenih ali konvencionalnih semen, hrane in krme.
The Commission does not accept amendment 12 stating in a recital that a European paediatric form should be set up for the collection of data on medicinal products authorised in the Member States.
Komisija ne sprejme predloga spremembe 12, ki v uvodni izjavi navaja, da je treba oblikovati evropski pediatrični obrazec za zbiranje podatkov o zdravilih, ki so bila odobrena v državah članicah.
The Commission does not accept amendment 13 providing in a recital that, where there is cause for concern and a risk management system is set after marketing authorisation, this system should operate under the responsibility of the Paediatric Committee.
Komisija ne sprejme predloga spremembe 13, ki v uvodni izjavi navaja, da je, kjer obstaja poseben razlog za skrb in se sistem obvladovanja tveganja vzpostavi po izdaji dovoljenja za promet, za delovanje tega sistema odgovoren Odbor za pediatrijo.
The Commission does not accept amendment 15 (second and third parts) concerning national clinical trials databases and the avoidance of the repetition of studies already performed in third countries.
Komisija ne sprejme predloga spremembe 15 (drugi in tretji del) v zvezi z nacionalnimi bazami podatkov kliničnih preiskav in izogibanjem ponavljanju študij, ki so že bile izvedene v tretjih državah.
The Commission does not accept amendment 18 (second part) introducing amongst the objectives of the Regulation a specific mention of medicinal products intended for the treatment of rare congenital conditions suffered by children.
Komisija ne sprejme predloga spremembe 18 (drugi del), ki med različnimi cilji Uredbe izrecno omenja zdravila, namenjena za zdravljenje redkih prirojenih bolezni otrok.
The Commission does not accept amendment 19 as regards the content of the new Article 2a tasking the Member States with collecting available data on existing uses of medicinal products and drawing up of an inventory of therapeutic needs within a year.
Komisija ne sprejme predloga spremembe 19 v zvezi z vsebino novega člena 2a, ki od držav članic zahteva, da v enem letu zberejo razpoložljive podatke o obstoječih uporabah zdravil in da oblikujejo seznam terapevtskih potreb.
The Commission does not accept amendment 19 as regards the content of the new Article 2c concerning the implementing strategy of the European network.
Komisija ne sprejme predloga spremembe 19 v zvezi z vsebino novega člena 2c o izvedbeni strategiji evropske mreže.
The Commission does not accept amendment 19 as regards the content of the new Article 2d tasking the Commission and the Member States with the establishment of a research programme into the paediatric use of medicinal products which are not protected by a patent of supplementary protection certificate.
Komisija ne sprejme predloga spremembe 19 v zvezi z vsebino novega člena 2d, ki od Komisije in držav članic zahteva, da ustanovijo raziskovalni program za pediatrično uporabo zdravil, ki niso zaščitena s patentom ali dodatnim varstvenim certifikatom.
The Commission does not accept amendment 19 insofar as it entails moving the survey, inventory and network (Articles 41, 42 and 43 of the Commission proposal) to a new Chapter 1a.
Komisija ne sprejme predloga spremembe 19, če povzroča prenos raziskave, seznama in mreže (členi 41, 42 in 43 predloga Komisije) v novo poglavje 1a.
The Commission does not accept amendment 23 limiting the number of representatives of the Commission and of the Executive Director of the Agency which may attend Paediatric Committee meetings.
Komisija ne sprejme predloga spremembe 23 o zmanjšanju števila predstavnikov Komisije in izvršnega direktorja agencije, ki se lahko udeležujejo sestankov Odbora za pediatrijo.
The Commission does not accept amendment 24 which provides that all direct interests of members of the Paediatric Committee relating to the pharmaceutical industry shall be entered in a publicly accessible register.
Komisija ne sprejme predloga spremembe 24, ki navaja, da se vsi neposredni interesi članov Odbora za pediatrijo, povezani s farmacevtsko industrijo, vnesejo v register, ki je dostopen javnosti.
The Commission does not accept amendment 25 aiming at specifying, in the provision listing the tasks of the Paediatric Committee, that scientific assistance will be free of charge.
Komisija ne sprejme predloga spremembe 25, ki pri navajanju nalog Odbora za pediatrijo določa, da bo znanstvena pomoč brezplačna.
The Commission does not accept amendment 30 concerning the inclusion, in the marketing authorisation application for a new product, of details of on-going paediatric studies and the time-frame for their completion, to address the situation where it will not be appropriate to conduct studies in children in parallel with studies in adults.
Komisija ne sprejme predloga spremembe 30 v zvezi z vključitvijo podatkov o trenutnih pediatričnih raziskavah in časovnega okvira, v katerem naj bi se zaključile, v vlogo za dovoljenje za promet novega proizvoda za obravnavanje položaja, ko ne bo primerno izvajanje raziskav pri otrocih vzporedno z raziskavami pri odraslih.
The Commission does not accept amendment 32 which provides that Article 9(1) of the Regulation should also apply to medicinal products falling within the scope of Article 3(2)(b) of Regulation (EC) No 726/2004 (optional scope of the centralised procedure).
Komisija ne sprejme predloga spremembe 32, ki navaja, da se mora člen 9(1) Uredbe uporabljati tudi za zdravila, ki spadajo v področje uporabe člena 3(2)(b) Uredbe (ES) št. 726/2004 (neobvezno področje uporabe centraliziranega postopka).
The Commission does not accept amendment 33, which makes producers financially responsible for information campaigns for the public.
Komisija ne sprejme spremembe 33, ki proizvajalcem nalaga finančno odgovornost za kampanje za obveščanje javnosti.
The Commission does not accept amendment 4 which adds a new recital saying that a “study devoted to the impact of the directive” shows the relevance of fixed sizes for vulnerable consumers for the following reasons:
Komisija spremembe 4, ki dodaja novo uvodno izjavo in ki trdi, da „študija o vplivu direktive“ kaže pomen določenih velikosti za najbolj ranljive potrošnike, ne sprejme zaradi naslednjih razlogov:
The Commission does not accept amendment 4, which provides in very general terms that the court must have a margin of discretion in applying the Regulation.
Komisija zavrne predlog spremembe 4, ki v zelo splošnem smislu predvideva, da se sodnik svobodno odloča o uporabi Uredbe.
The Commission does not accept amendment 40 (last part) aimed at establishing that the Paediatric Committee propose a deadline for the submission of an amended paediatric investigation plan.
Komisija ne sprejme predloga spremembe 40 (zadnji del), ki določa, da Odbor za pediatrijo predvidi rok za predložitev spremenjenega načrta pediatričnih preiskav.
The Commission does not accept amendment 41 aimed at defining the detailed rules governing the interaction between the applicant, the rapporteur and the Paediatric Committee.
Komisija ne sprejme predloga spremembe 41, ki določa natančna pravila o vzajemnem delovanju vlagatelja, poročevalca in Odbora za pediatrijo.
The Commission does not accept amendment 43 (third part) aimed at dictating that paediatric information contained in product information (the summary of product characteristics and patient information leaflet) should always clearly state the paediatric indications approved and those that are not.
Komisija ne sprejme predloga spremembe 43 (tretji del), ki določa, da morajo pediatrični podatki v podatkih o proizvodu (povzetek glavnih značilnosti zdravila in navodila za uporabo) vedno jasno navajati, katere pediatrične indikacije so odobrene in katere ne.
The Commission does not accept amendment 44 (second part) aimed at creating a European competition to design a logo to be used to label medicines for children.
Komisija ne sprejme predloga spremembe 44 (drugi del), ki obravnava pripravo evropskega natečaja za oblikovanje loga, ki se bo uporabljal za označevanje zdravil za otroke.
The Commission does not accept amendment 5 on the grounds that there is no evidence that liberalization gives rise to a proliferation of pack-sizes and market complications; in particular not in the sectors that Parliament wants to add.
Komisija ne sprejme spremembe 5, ker ni dokaza, da je liberalizacija povzročila močno povečanje različnih velikosti pakiranj in zaplete na trgu; zlasti ne v sektorjih, ki jih želi Parlament dodati.
The Commission does not accept amendment 52 (first part relating to patents) which excludes an extension of the supplementary protection certificate for products whose active substance has already benefited from a patent covering the paediatric use or formulation.
Komisija ne sprejme predloga spremembe 52 (prvi del v zvezi s patenti), ki izključuje podaljšanje veljavnosti dodatnega varstvenega certifikata za proizvode, katerih zdravilne učinkovine so že imele koristi od patenta, ki pokriva isto pediatrično uporabo ali formulacijo.
The Commission does not accept amendment 53 which aims to exclude the possibility of more than one extension of the supplementary protection certificate per medicinal product.
Komisija ne sprejme predloga spremembe 53, ki izključuje možnost več kot enega podaljšanja dodatnega varstvenega certifikata na zdravilo.
The Commission does not accept amendment 54 which aims to offer the applicant an additional possibility which would simplify the marketing authorisation procedure for orphan drugs.
Komisija ne sprejme predloga spremembe 54, ki vlagatelju ponuja dodatno možnost, ki bi poenostavila postopek za pridobitev dovoljenja za promet zdravil sirote.
The Commission does not accept amendment 6 (second part) tasking the Paediatric Committee with the ethical assessment of paediatric investigation plans.
Komisija ne sprejme predloga spremembe 6 (drugi del), ki od Odbora za pediatrijo zahteva etično presojo načrtov pediatričnih preiskav.
The Commission does not accept amendment 65 which aims to promote the harmonisation of national measures enacting penalties, but does not provide any means to ensure such harmonisation.
Komisija ne sprejme predloga spremembe 65, ki spodbuja usklajevanje nacionalnih ukrepov v zvezi s kaznimi, ne navaja pa načina za zagotovitev takega usklajevanja.
The Commission does not accept amendment 68 which aims to reduce the deadline for submission of an application for an extension of the supplementary protection certificate.
Komisija ne sprejme predloga spremembe 68, ki skrajšuje rok za predložitev vloge za podaljšanje dodatnega varstvenega certifikata.
The Commission does not accept amendment 70 which aims to introduce transitional measures relating to paediatric investigation plans.
Komisija ne sprejme predloga spremembe 70, ki uvaja prehodne ukrepe v zvezi z načrtom pediatričnih preiskav.
The Commission does not accept amendment 77 on the exclusion of legal services; this is not required given that Article 3 already provides that in case of conflict between the provisions of the Services Directive and a provision of another Community instrument governing specific aspects of the services activity the provision of the latter will prevail.
Komisija ne sprejme spremembe 77 o izključitvi pravnih storitev; to ni potrebno, saj že člen 3 določa, da v primeru nasprotja med določbami Direktive o storitvah in določbo drugega instrumenta Skupnosti, ki ureja posebne vidike storitvenih dejavnosti, prevlada slednja.
The Commission does not accept amendments 11 and 22, which would introduce the restitutio in integrum principle in quantifying damages for personal injury victims.
Komisija zavrne predloga sprememb 11 in 12, s katerima naj bi se vključilo načelo „restitutio in integrum“ (vrnitev v prejšnje stanje) pri določanju pogodbeno dogovorjenih odškodnin, dodeljenih poškodovanim osebam.
The Commission does not accept amendments 11 and 46 aimed at introducing flexibility to the deadline for placing on the market existing medicinal products newly authorised for children.
Komisija ne sprejme predlogov sprememb 11 in 46, ki uvajata odstopanje od roka za dajanje v promet obstoječih zdravil, ki so bila za otroke odobrena nedavno.
The Commission does not accept amendments 14 and 51 which aim to remove the requirement for a medicinal product to be authorised in all Member States as a prerequisite for the extension of the supplementary protection certificate.
Komisija ne sprejme predlogov sprememb 14 in 51, s katerimi se črta zahteva po odobritvi zdravila v vseh državah članicah kot predpogoj za podaljšanje veljavnosti dodatnega varstvenega certifikata.
The Commission does not accept amendments 3 and 16 aimed at moving recital (29) to recital (4a), while maintaining the text of the recital unchanged.
Komisija ne sprejme predlogov sprememb 3 in 16, ki spreminjata uvodno izjavo (29) v uvodno izjavo (4a), hkrati pa ohranjata njeno besedilo.
The Commission does not accept amendments 36, 37 and 38 providing that applications for agreement of paediatric investigation plans shall include a summary report; reducing the deadline for validation of such applications by the Agency from 30 to 10 days; and removing the deadline for industry to submit and discuss its plans for paediatric studies with the Paediatric Committee.
Komisija ne sprejme predlogov sprememb 36, 37 in 38, ki navajajo, da vloge za dogovor za načrte pediatričnih preiskav vključujejo zbirno poročilo; skrajšanje roka za potrditev teh vlog s strani agencije z desetih na trideset dni; in odstranitev roka, do katerega mora industrija predložiti in obravnavati načrte za pediatrične študije z Odborom za pediatrijo.
The Commission does not accept amendments 47 and 48, which provide for the compulsory inspection of ships which have failed to notify their arrival in port and ships which have not had all their faults rectified.
Komisija ne sprejema sprememb 47 in 48, ki predvidevata uvedbo obvezne inšpekcije ladij, ki niso obvestile pristanišča o svojem prihodu, in tistih, pri katerih niso bile odpravljene vse pomanjkljivosti.
The Commission does not accept amendments 47, 48, 49 and 83 which aim to duplicate or amend some of the pharmacovigilance provisions contained in the Community pharmaceutical legislation.
Komisija ne sprejme predlogov sprememb 47, 48, 49 in 83, ki podvajajo ali spreminjajo nekatere določbe o farmakovigilanci iz farmacevtske zakonodaje Skupnosti.
The Commission does not accept the deletion of the second paragraph of Article 5 of the common position covering the system for indemnity in the event of a terrorist attack.
Komisija ne sprejme razveljavitve drugega odstavka člena 5 skupnega stališča v zvezi z mehanizmom odškodnine v primeru terorističnega napada.
The Commission does not accept the last sentence of this amendment, which suggests that setting up a compulsory insurance scheme should not affect existing insurance schemes.
Komisija ne sprejme zadnjega stavka te spremembe, ki se ga razume, kot da vzpostavitev obveznega zavarovalnega sistema ne bi smela imeti posledic za obstoječe ureditve zavarovanja.
The Commission does not accept the second and third parts of the amendment, because it considers that these elements would tend, at this juncture, to exacerbate the difficulty of finding overall agreement on the proposal, and that they can be better addressed in another context.
Komisija ne sprejme drugega in tretjega dela spremembe, ker meni, da bi ti elementi v tem trenutku utegnili otežiti dosego splošnega soglasja o predlogu ter da bi jih bilo lažje obravnavati v drugačnem okviru.
The Commission does not accept these amendments as the first undermines the principle of unicity of the budget and the second would have the effect of depriving the Agency of about 40% of the financial resources allocated to the development of safety regulations, compliance checks by the Member States and accident analysis.
Komisija navedenih predlogov sprememb ne sprejme, ker prvi škoduje načelu enotnosti proračuna, drugi pa bi Agencijo prikrajšal za približno 40 % finančnih virov, namenjenih razvoju varnostnih predpisov, nadzoru skladnosti držav članic in analizi nesreč.
The Commission does not accept this amendment, since according to Article 17 (2) of the proposed Directive, this issue should be left to the discretion of the Member States, in line with the subsidiarity principle.
Komisija te spremembe ne sprejme, ker mora biti to vprašanje v skladu s členom 17(2) in načelom subsidiarnosti prepuščeno državam članicam.
The Commission does not accept this approach.
Komisija tega pristopa ne sprejema.
The Commission does not accept this deletion because restrictions or prohibitions need to be well reasoned and justified in line with national conditions.
Komisija ne sprejema tega črtanja, saj morajo biti omejitve ali prepovedi dobro utemeljene in upravičene v skladu z nacionalnimi pogoji.
The Commission does not address this problem.
Komisija tega vprašanja ne obravnava.
The Commission does not address this problem.
Komisija tega vprašanja ne obravnava..
The Commission does not agree that intellectual property rights held by public authorities should be among the list of grounds for limiting public access to spatial data.
Komisija se ne strinja, morajo biti pravice intelektualne lastnine na seznamu razlogov za omejitev dostopa javnosti do prostorskih podatkov.
The Commission does not agree with the EP assumption that the general methodology used for the risk assessment of foodstuffs would not be applicable for that of nanomaterials in food (amendment 6) and that, until specific test methods are developed, no food with nanomaterials should be put on the EU market (amendment 120).
Komisija se ne strinja s predpostavko EP, da se splošna metodologija za oceno tveganja živil ne more uporabljati za oceno tveganja nanomaterialov v živilih (sprememba 6) in da se na trg EU ne sme dati nobenih živil z nanomateriali, dokler se ne razvijejo posebne preskusne metode (sprememba 120).
The Commission does not agree with the new recital 1a, which states that the Regulation must be interpreted in accordance with international law.
se Komisija ne strinja z novo uvodno izjavo 1a, po kateri je treba uredbo razlagati v skladu z mednarodnim pravom.
The Commission does not agree with this approach, which reflects the current legal situation, as this would reduce the flexible use of the EU funds within the Member States and entail additional administrative work and costs.
Komisija se ne strinja s tem pristopom, ki izraža sedanje pravno stanje, saj bi to zmanjšalo prožnost uporabe sredstev EU v državah članicah in povzročilo dodatno upravno obremenitev in stroške.
The Commission does not agree with this approach, which reflects the current legal situation, as this would reduce the flexible use of the EU funds within the Member States and entail additional administrative work and costs.
Komisija se ne strinja s tem pristopom, ki odraža sedanje pravno stanje, saj bi to zmanjšalo prožnost uporabe sredstev EU v državah članicah in povzročilo dodatno upravno obremenitev in stroške.
The Commission does not agree with this rejection.
Komisija se s to zavrnitvijo ne strinja.
The Commission does not appear to have a set of instruments enabling it to assess adequately the quality of government expenditure in the Member States.
Zdi se, da Komisija ne razpolaga z vrsto instrumentov, ki bi ji omogočali ustrezno presojo kakovosti vladnih izdatkov v državah članicah.
The Commission does not consider it appropriate to put forward any proposal for revising the Directive until the diagnostic phase of the review of the consumer acquis communautaire (the “acquis”) is concluded (see Annex III).
Komisiji meni, da predložitev kakršnega koli predloga za spremembo Direktive ni primerna, dokler diagnostična faza pregleda pravnega reda Evropskih skupnosti o varstvu potrošnikov („pravni red“) ni končana (glej Prilogo III).
The Commission does not consider it justified to depart from the horizontal procedural rules agreed to implement the EU acquis.
Komisija meni, da odstopanje od horizontalnih postopkovnih pravil, sprejetih za izvajanje pravnega reda EU, ni upravičeno.
The Commission does not consider it necessary to propose amendments to the Directive at this stage but will prioritise addressing the remaining transposition issues with the Member States concerned, mainly in relation to the scope of the exception provided for in Article 4(5) of the Directive.
Komisija meni, da v tej fazi ni treba predlagati sprememb Direktive, bo pa z zadevnimi državami članicami prednostno obravnavala preostala vprašanja glede prenosa, ki se nanašajo predvsem na obseg izjeme iz člena 4(5) Direktive.
The Commission does not consider it useful to propose an EU mechanism for relocating applicants for international protection for the moment.
Po mnenju Komisije predlog mehanizma EU za premestitev prosilcev za mednarodno zaščito v tem trenutku ne bi prinesel koristi.
The Commission does not consider such an approach to be appropriate for the EU.
Komisija meni, da tak pristop ni primeren za EU.
The Commission does not consider that a compulsory registration system would be an appropriate option.
Komisija meni, da sistem obvezne registracije ne bi bila ustrezna možnost.
The Commission does not consider that another major alteration of the legislative architecture is necessary for the next MFF period, although some improvements are being proposed and the overall investment is being stepped up.
Komisija meni, da v obdobju naslednjega večletnega finančnega niso potrebne nadaljnje večje spremembe zakonodajnega okvira na tem področju, vendar pa predlaga nekatere izboljšave in si prizadeva za povišanje splošne ravni naložb.
The Commission does not consider that any change is needed to the rules regarding organisation of working time for workers concerned with the carriage of passengers on regular urban transport services.
Komisija meni, da spremembe pravil v zvezi z organizacijo delovnega časa za delavce, ki se ukvarjajo s prevozom potnikov v storitvah rednega mestnega prevoza, niso potrebne.
The Commission does not consider that it is necessary to show that competitors have exited the market in order to show that there has been anticompetitive foreclosure.
Komisija meni, da ni potrebno pokazati, da so konkurenti zapustili trg, da bi dokazali, da je šlo za protikonkurenčno omejevanje dostopa.